Med eTech has the opportunity to work with some of the top, global key opinion leaders to deliver Phase l-lV drug and medical device studies (class l-lll).
Med eTech's experience, coupled with our strong, PI relationships, suitably places Med eTech to make sure your trial(s) are delivered on time and within the agreed budget.
Our global regulatory experts can add input, strategy, based on their knowledge and in depth understanding of the local country specific regulatory landscape.
Med eTech's unique business model of being both a CRO and an organization that will undertake neglected global disease clinical trials at costs following global health access and equity policies. Med eTech will also accept commercial clinical trials from sponsors looking at parasitic or fungal diseases to test their IMP or device in a clinical setting.
Neglected Diseases
Med eTech work in a consortium that are all experts in their particular field for this specialised area of research. The members include but not limited to:
We are interested in parasitic and fungal diseases as:
and more ...
Investigational Medicinal Product (IMP)
Med eTech has worked on IBD, and other GIT studies.
Endocrinology for Pre-Diabetes and Diabetes Type ll, Oncology, Ophthalmology, Neurology, and other IMP clinical trials
Med eTech has managed several clinical trials in Ophthalmology, as seen in an aging population there are several ophthalmic disorders occurring with significant healthcare cost implications. Research into novel treatment options therefore, remains a priority.
Med eTech have expertise with our CSO in Parasitic and Fungal Diseases. Over many years Professor Wasan has formulated a new oral drug that Med eTech hope to manage a Phase ll clinical trial in late 2024 / early 2025. Phases l and lb clinical trials have been undertaken.
We see exciting innovation and changing dynamics within medical device clinical trials. Devices are smaller, there are image advancements, remote monitoring and software enabled smart devices especially in Diabetes Types l and ll changing the way we care and create new business models.
Med eTech provide software enabled clinical solutions for all your clinical trial requirements.
Medical Devices
Medical devices covers a wide range of products including syringes, dressings, surgical tools, scanners, software machines and some medical apps.
Medical devices have Classes not Phases as do IMP clinical trials.
We see exciting innovation and changing dynamics within medical device clinical trials. Devices are smaller, there are image advancements, remote monitoring and software enabled smart devices especially in Diabetes Types l and ll changing the way we care and create new business models.
Med eTech provide software enabled clinical solutions for all your clinical trial requirements.
Nutraceuticals
Health benefits associated with food and beverages can be translated into 'Health Claims'.
Human clinical trials are critical for the substantiation of Health Claims by the European Food Safety Authority - EFSA and the US Food and Drug Administration.
In terms of Consumer Behaviour, perception and purchase intention increase when a product has an associated Health Claim.
Trust is the most important factor when consumers are purchasing functional foods.
When we undertake nutraceutical studies on subjects we unlock the bodies full potential for being in the best nutritional state of health.
Med eTech bring new insights that differentiate the nutraceutical product. Med eTech will deliver robust data which is essential for an EU EFSA Claim application and subsequent product marketing efficacy claim. The US market for supplements is not as stringent so by utilising Med eTech expertise this will set you apart from other companies.
Our studies have included but not limited to; the study of the microbiome, gut, digestion, pre and post probiotics vitamins, food supplements, HbA1c testing for pre-diabetes. Nutraceutical studies vary depending on what you are studying it is a very interesting area of research.
Functional Food, Beverages & Ingredients
Medical Foods
Microbiome-based Therapeutics 
Supplements
Infant Formula
Pre & ProbioticsObjective: Evaluate on 12 healthy subjects the bio-availability of proteins consumed at different doses. The concentration of the proteins or protein derivatives in blood was measured every 20 minutes for 2 hours after the study product consumption.
Timelines for each subject: After a screening visit, the eligible subjects were invited on the same week to one visit involving the study product consumption and blood sampling.
Outcomes: Protein derivatives with suspected health effects have been detected when the study product was consumed at higher doses. These results were used as preliminary outcomes for a second clinical study testing the health effects of the proteins on a larger population.
Objective: Evaluate on 700 healthy paediatric subjects the preventive effects of a probiotic consumption on respiratory infections. Half of the subjects consumed the study product and the other half a placebo.
Timelines for each subject: After a screening visit, the eligible subjects were invited for a randomisation visit and were provided with study product or placebo for a daily consumption over 4 months.
Every time a subject was experiencing a respiratory infection, he was invited for a visit at clinical site to confirm the infection diagnostic.
At the end of the 4 months, the subjects were invited for a final visit.
Outcomes: Positive effects of the probiotic have been demonstrated for the prevention of the respiratory infection. The final clinical report is in preparation. An EFSA claim is targeted by the sponsor.
Objective: Evaluate on 63 pre-diabetic subjects, but otherwise healthy, the evolution of type-2 diabetes markers (OGTT, Insulin, HbA1c, ..). Two plant extracts have been tested as study products and compared to a placebo (21 subjects in each arm).
Timelines for each subject: After a screening visit, the eligible subjects were invited for a randomization visit and were provided with one of the study products or with placebo for a daily consumption over a 12 weeks period.
Cardiovascular Health
Med eTech has experience in Nuclear Medicine Cardiology Diagnostic procedures including cardiac imaging. Several clinical studies have shown the benefit and safety of contrast enhancement for improving both endocardial border definition and diagnostic confidence for the cardiologist.
More ...
Professor Leiper has published in many scientific and medical journals about many different therapeutic areas in medicine and written a book on lung ventilation and perfusion scanning and the use of Technegas using the Positive Ventilation Delivery System for the unconscious Intensive Care Patient.
Professor Leiper has attended many international conferences and established over thirty partnerships for her CRO.
Professor Leiper also was part of the First Scottish Stroke Audit Team which set the standards for Stroke and opened up dedicated stroke units and paved the way for the standards used now routinely from arrival in Emergency to being treated in a specialist Stroke Unit.
Wasan's research focuses on lipid-based drug delivery and the interaction between lipoprotein and pharmaceuticals. He has published more than 550 peer-reviewed articles and abstracts. He has a Public Leadership Credential from Harvard Kennedy School 2021. He is a founding member and currently co-director of UBC's Neglected Global Diseases Initiative and an distinguished university scholar adjunct Professor in the Department of Urologic Sciences in the Faculty of Medicine at UBC.
Dr. Wasan has received numerous awards (over 25) for his contributions to health sciences and is currently a fellow of the Canadian Academy of Health Sciences (one of the highest honours in Canada), the Canadian Society for Pharmaceutical Sciences and the American Association of Pharmaceutical Scientists, a fellow member of the Royal Society of Medicine (London, UK) and an elected member of the Sigma Xi Scientific Research Honor Society. He is the co-inventor of a novel oral amphotericin B formulation to treat leishmaniasis and systemic fungal infections that is cost-effective, safe, tropically stable, accessible and with positive human phase 1 safety data.
We are thrilled to announce that Dr. Kishor Wasan has joined Med eTech Innovation as the new Director and Chief Scientific Officer (CSO). Prof. Wasan was awarded the MD Anderson Cancer Center Distinguished Alumnus Award Honour for 2025 and will be presenting a lecture in Houston in March 2025. With his extensive background in lipid-based drug delivery and pharmaceutical sciences, Professor Wasan brings a wealth of knowledge and expertise to our team. Med eTech Innovation Ltd. can now also offer drug discovery and development as well as the many therapeutic areas of medicine in which we can manage clinical trials. This makes Med eTech Innovation a niche company as we can offer bench to bedside.
Professor Wasan has developed a novel oral formulation of Amphotericin B or OAmB to treat fungal and parasitic infections. This new formulation aims to overcome the limitations of the traditional intravenous form, such as toxicity, high costs, and the need for hospital administration.
The oral version is designed to be less toxic, more cost-effective, and easier for patients to take, potentially improving adherence to treatment. This will be a game-changer for humanitarian use as it can be used remotely so patients don't have to travel long distances for treatment.
We at Med eTech would like to nominate Dr. Kishor Wasan for the Order of Canada honour for his extensive work in and contributions toward the field of neglected global diseases, particularly in regard to the discovery, development, and diagnostics for long-neglected tropical diseases that have a disproportionate impact on impoverished communities and peoples around the globe.
As co-founder and the first director of the Neglected Global Diseases Initiative (NGDI) at the University of British Columbia, as well as then-CIHR/iCo Therapeutics Research Chair in Drug Delivery for Neglected Global Diseases, Dr. Wasan spearheaded a monumental effort to discover and develop drugs to treat and prevent largely under- and un-addressed tropical disease outbreaks throughout the developing world. This included building partnerships and leading major research efforts and programs to innovate and streamline neglected disease research while making a significantly positive impact on global health and global health education. As NGDI Director, Dr. Wasan successfully secured more than $50 million for neglected disease projects and programs across the developed world, and under his leadership, NGDI earned the #1 world ranking by the Universities Allied for Essential Medicines for Global Health Principles and Global Health Research in 2013.
As a result of Dr. Wasan's efforts, The University of British Columbia (UBC) became the first university in Canada to develop a strategy for enhancing global access to its technologies. UBC's University-Industry Liaison Office, in collaboration with the UBC chapter of Universities Allied for Essential Medicines (UAEM), established a mandate and developed principles that provide the developing world with access to UBC technologies.
In addition to his transformative work in neglected global diseases, I believe Dr. Wasan's position as worthy nominee of the Order of Canada is bolstered by his previous research in and contributions toward the pharmaceutical community's understanding of drug lipoprotein interactions in drug development. In 2008, Dr. Wasan established the importance of drug lipoprotein interactions in drug development, a discovery that led the US Food and Drug Administration to incorporate these principles and investigations as part of the IND package for new drug development: Dr. Wasan's research and discovery is outlined in a January 2008 paper: Wasan, K.M., Brocks, D.R., Lee, S.D., Sachs-Barrable, K. Thornton, S.J. (2008). Impact of lipoproteins on the biological activity and disposition of hydrophobic drugs: implications for drug discovery. Nature Reviews Drug Discovery, 7(1), 84-99.
In May 2008, UBC signed the first licensing deal in accordance with these principles when Vancouver company iCo Therapeutics Inc. licensed a new oral formulation of Amphotericin B developed at the UBC Wasan Lab by Dr. Wasan, then-Professor and Chair in the Division of Pharmaceutics & Biopharmaceutics, and Dr. Ellen Wasan, Adjunct Professor in the Faculty of Pharmaceutical Sciences.
Dr. Wasan was also instrumental in establishing Global Health Principles at UBC, whose mandate is to develop technologies for the developing world at or below development cost. The oral amphotericin B technology funded by the Gates Foundation was one of the technologies in this program.
Last but certainly not least is one of Dr. Wasan's most notable achievements at the University of Saskatchewan. Dr. Wasan is responsible for establishing and garnering accreditation for the Doctor of Pharmacy Program at the University of Saskatchewan College of Pharmacy and Nutrition. As a result of his efforts, Dr. Wasan received the Award of Merit from the Pharmacy Association of Saskatchewan in 2021.
In short., Dr. Wasan's contributions to academia, drug development, and tropical disease research are not only many but considerable, and have undoubtedly made a significantly positive imp[act on the world of pharmaceuticals and global health. It is my sincere belief that Dr. Wasan's extensive resume of accomplishments and the massive impact his work and commitment to making a positive difference on the industry, society, and the world positions him as an eminently qualified nominee for Order of Canada Honors.
Dr. Kishor M. Wasan, PLC (Harvard) R.Ph., Ph.D., FAAPS, FCAHS, FCSPS
Fellow Member, Royal Society of Medicine (UK)
Former Dean & Professor (Retired), University of Saskatchewan
Adjunct Professor & Distinguished University Scholar
Co-Director & Co-Founder, Neglected Global Diseases Initiative-UBC
Department of Urologic Sciences
Faculty of Medicine
Faculty of Pharmaceutical Sciences
The University of British Columbia
Vancouver, BC, Canada V6T 1Z3
Department of Urologic Sciences
Neglected Global Diseases Initiative
University Distinguished Scholar
Director of Research, iCo Therapeutics Inc., April 15th 2020-Current
Adjunct Professor and Distinguished University Scholar, UBC Pharmaceutical Sciences; August 2014-Current
Professor (Retired) and Dean, College of Pharmacy and Nutrition, University of Saskatchewan; August 2014-April 15th 2020 (Retired)
Associate Dean of Research and Graduate Affairs, Faculty of Pharmaceutical Sciences, UBC; Sept. 2011-August 2014 Professor (Tenured) and Division Chair (2001-2010), Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia; July 1st 2005 to July 2014.
Co-Director, Nanomedicine and Drug Delivery Graduate Stream, January 2011-July 2014;
Director and Co-Founder of the NGDI-UBC June 2009-June 2014
CIHR University-Industry Research Chair, December 1st 2003 to November 30th 2008; Renewed April 1st 2009-March 31st 2014 (CIHR/iCo Therapeutics Research Chair in Drug Delivery for Neglected Global Diseases). Affiliated Investigator, Vancouver Coastal Health Research Institute, September 6th 2005 to Present. Affiliated Faculty, Centre for Higher Order Structure Elucidation (C-HORSE; www.chem.ubc.ca/chorse/faculty.html) at UBC, 2006 to Present
Member, Interdisciplinary Oncology Program, UBC, 2006 to Present
Mentor, CIHR Health Research Training Program in Transplantation, UBC, 2009 to Present
Distinguished University Scholar; University of British Columbia, April 1st 2004 to Present Chair, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia; January 1st 2001 to December 31st 2009.
Associate Professor (Tenured), Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia; July 1st 2000 to June 30th 2005.
Natl. Director, Summer Student Research Program for Canadian Pharmacy Students; January 1st 2001 to June 2010. Assistant Professor, Division of Pharmaceutics and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of British Columbia; February 1st 1995 to June 30th 2000.
Director of Summer Student Research Programs, Faculty of Pharmaceutical Sciences, University of British Columbia; July 1st 1997 to October 31st 2001.
Post-Doctoral Fellowship, Department of Cell Biology, Research Institute, Cleveland Clinic Foundation (Supervisor; Richard E. Morton Ph.D.); January 1994 to December 1994.
Post-Doctoral Fellowship, Department of Thoracic, Head & Neck Medical Oncology, M.D. Anderson Cancer (Supervisor; Roman Perez-Soler M.D.); October 1993 to December 1994. (Cross-appointment)
